Zobrazeno 1 - 10 of 17 pro vyhledávání: '"S. H. Goey"'
2
Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands
Autor: Usman Iqbal, F. Joulain, S. H. Goey, N. Muszbek, D.R. Ferry, S. Naoshy, Dara Stein, K. A. Payne
Publikováno v: International journal of colorectal disease. 29(10)
This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. A cross-sectional study was conducted in five hospitals in the Nether
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72fc1ed04ad26676147ddb441ac19b1a
https://pubmed.ncbi.nlm.nih.gov/25080148
Zobrazit plný text záznamu
3
Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: A phase IA—B study
Autor: Th. Wiggers, A. M. M. Eggermont, R. L. H. Bolhuis, S. H. Goey, R. Oskam, G. Stoter
Publikováno v: Annals of Oncology. 7:317-319
Although high response rates have been reported with hepatic arterial infusion of chemotherapy for colorectal cancer metastasized to the liver, convincing evidence of improved survival is lacking [1]. Therefore the search for new drugs for this appli
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13c03190b2b9714bb8fe0b946b91f456
https://doi.org/10.1093/oxfordjournals.annonc.a010579
Zobrazit plný text záznamu
4
Duodenal metastasis: an uncommon cause of occult small intestinal bleeding
Autor: A, Loualidi, P F M J, Spooren, M J A L, Grubben, C E M, Blomjous, S H, Goey
Publikováno v: The Netherlands journal of medicine. 62(6)
Duodenal metastases are a very uncommon and peculiar cause of upper gastrointestinal bleeding. However, they should be considered in a patient presenting with upper gastrointestinal bleeding and a previous history of malignancy. The importance of rec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4e2e8058e992005f55f02eaed3bb544e
https://pubmed.ncbi.nlm.nih.gov/15460501
Zobrazit plný text záznamu
5
Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma
Autor: B. Osterwalder, Wim H. J. Kruit, S. H. Goey, H. Poliwoda, F. Calabresi, G. Stoter, A. Lindemann, Rolf A. Stahel
Publikováno v: British Journal of Cancer
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aeb8e4151ddab6d34f6e1c0b84cdccf
https://doi.org/10.1038/bjc.1995.256
Zobrazit plný text záznamu
6
Intraperitoneale Therapie des Ovarialkarzinoms mit T-Lymphozyten, präinkubiert mit bispezifischen monoklonalen Antikörpern und Interleukin-2
Autor: S. H. Goey, A. Logmans, C. H. J. Lamers, R. L. H. Bolhuis, J. B. M. Z. Trimbos, A. M. M. Eggermont, G. Stoter, Sven O. Warnaar, F. J. Cleton
Publikováno v: European Surgery. 27:90-92
Background Ovarian cancer refractory to chemotherapy has a very poor prognosis and no standard treatment options. In a phase I–II study patients with recurrent disease restricted to the peritoneal cavity received intraperitoneal (i.p.) immunotherap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e08d5eac1311cbb7ba85780d6445e04
https://doi.org/10.1007/bf02602251
Zobrazit plný text záznamu
7
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFNα) in metastatic melanoma
Autor: R. L. H. Bolhuis, S. H. Goey, J. R. T. Monson, Rolf A. Stahel, Gerrit Stoter, P. H. M. Mulder, Wim H. J. Kruit, F. Calabresi, A. M. M. Eggermont, RH Mertelsmann, E. E. Holdener
Publikováno v: British Journal of Haematology. 79:84-86
A multicentre study of IL2 and IFN alpha has been performed in 58 patients with metastatic melanoma. The scheme consisted of IL2 3.0 BRMP MU/m2/d as a continuous infusion for 4 d combined with subcutaneous administration of IFN alpha 6 MU/m2/d, day 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2486e696f4b61eee160827ef8e510cb
https://doi.org/10.1111/j.1365-2141.1991.tb08128.x
Zobrazit plný text záznamu
9
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma
Autor: M. de Boer-Dennert, M.E.L. van der Burg, J.H.M. Schellens, S. H. Goey, A. S. T. Planting, Jaap Verweij, Ch.J. Vecht, G. Stoter
Publikováno v: European journal of cancer (Oxford, England : 1990). (11)
The results of cytostatic therapy in metastatic melanoma are very disappointing. In phase II studies with high-dose cisplatin regimens, a remarkably high response rate was observed. In a phase I study with a short course of weekly cisplatin, combined
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::359a4a269f48f9b0b1bb45eb9b03ad07
https://pubmed.ncbi.nlm.nih.gov/8943692
Zobrazit plný text záznamu
10
Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes)
Autor: J W, Gratama, P I, Schmitz, S H, Goey, C H, Lamers, G, Stoter, R L, Bolhuis
Publikováno v: International journal of cancer. 65(2)
We treated 72 patients with metastatic renal-cell cancer according to 2 protocols consisting of two 5-week induction cycles of continuous i.v. high-dose interleukin-2 (IL-2), i.m. interferon-alpha (IFN alpha) and ex vivo IL-2-activated lymphocytes, f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5eabba867f892a0eae55b0a1fe55cba2
https://pubmed.ncbi.nlm.nih.gov/8567110
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje